All In Biotech

Free tool

FAERS Monitor: Pulmozyme

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 103532 or its brand name (Pulmozyme, Dornase Alfa). Reports on generic versions are filed under their own applications.

Reports

19,634

Serious

13,482

69% of reports

Hospitalization

10,667

Death reported

827

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • infective pulmonary exacerbation of cystic fibrosis2,316
  • cystic fibrosis1,776
  • hospitalisation1,320
  • pneumonia1,308
  • cough1,000
  • off label use975
  • infection950
  • no adverse event944
  • dyspnoea926
  • condition aggravated623
  • headache548
  • pulmonary function test decreased494
  • death491
  • fatigue475
  • malaise473

Reports by year received

View as table
YearReports
200415
200515
200618
200725
200844
200928
201085
2011277
2012217
2013240
2014438
2015793
20161,160
20171,288
20182,093
20193,972
20203,601
20211,263
20221,076
2023848
20241,040
2025662
2026435

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,034,525 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
infective pulmonary exacerbation of cystic fibrosisSignal2,316792.2752.21,051,941
cystic fibrosisSignal1,776505.2478.4607,144
pulmonary function test decreasedSignal494136.1124.158,682
hospitalisationSignal1,3209.38.89,723
infectionSignal9507.16.64,948
no adverse eventSignal9445.65.33,580
pneumoniaSignal1,3084.34.13,399
coughSignal1,0003.83.62,109
condition aggravatedSignal6232.22.0410
dyspnoea9261.81.6307
off label use9751.21.132
malaise4731.21.110
headache5480.90.92
fatigue4750.70.690
death4910.60.6127

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.